Contineum Therapeutics, Inc. Class A

XNASHealth care

Last traded price · USD

$9.69

−1.02%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $9.79
Volume: 214
Day's high: —
Day's low: —

In brief

Contineum Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $365M.
Its shares closed at $9.79 on 4 Nov 2026, down 5.8% over the past year.
From India you can buy CTNM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Contineum Therapeutics, Inc. (CTNM) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole CTNM share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade CTNM options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −22.6% (SPY −1.6%, XLV +13.5%). 3 months: −35.9% (SPY −0.4%, XLV +15.5%). 1 year: −5.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CTNM, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $9.79 was 20.2% below its 50-day average ($12.27) and 27.6% below its 200-day average ($13.52). It has closed below the 200-day for 35 sessions, since 17 Sep 2026. The 50-day average crossed below the 200-day on 21 Oct 2026, 10 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 11.1% of shares outstanding
3.7M shares were sold short at the 15 Oct 2026 settlement, 11.1% of the 33.0M shares outstanding; covering them would take 2.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
28% of the way up its 52-week range
Closed at $9.79 on 4 Nov 2026: 45.0% below the 52-week high of $17.79 (3 Sep 2026) and 45.6% above the low of $6.73 (19 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−22.6%

6 months−34.5%

1 year−5.8%

5 years—

Newswire

About

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Website

Notable moves

October 12, 2026
−35.99%
July 21, 2025
+29.89%
June 20, 2025
+30.41%

Newswire

About

Website

Notable moves

October 12, 2026
−35.99%
July 21, 2025
+29.89%
June 20, 2025
+30.41%

Contineum Therapeutics, Inc. Class A

XNASHealth care

Last traded price · USD

$9.69

−1.02%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:24 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $9.79
Volume: 214
Day's high: —
Day's low: —

In brief

Contineum Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $365M.
Its shares closed at $9.79 on 4 Nov 2026, down 5.8% over the past year.
From India you can buy CTNM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Contineum Therapeutics, Inc. (CTNM) shares from India?

Do I need the price of a whole CTNM share to invest?

How much can I invest in US stocks in a year?

Can I trade CTNM options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −22.6% (SPY −1.6%, XLV +13.5%). 3 months: −35.9% (SPY −0.4%, XLV +15.5%). 1 year: −5.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CTNM, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $9.79 was 20.2% below its 50-day average ($12.27) and 27.6% below its 200-day average ($13.52). It has closed below the 200-day for 35 sessions, since 17 Sep 2026. The 50-day average crossed below the 200-day on 21 Oct 2026, 10 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 11.1% of shares outstanding
3.7M shares were sold short at the 15 Oct 2026 settlement, 11.1% of the 33.0M shares outstanding; covering them would take 2.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
28% of the way up its 52-week range
Closed at $9.79 on 4 Nov 2026: 45.0% below the 52-week high of $17.79 (3 Sep 2026) and 45.6% above the low of $6.73 (19 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−22.6%

6 months−34.5%

1 year−5.8%

5 years—

Newswire

About

Website

Notable moves

October 12, 2026
−35.99%
July 21, 2025
+29.89%
June 20, 2025
+30.41%

Newswire

About

Website

Notable moves

October 12, 2026
−35.99%
July 21, 2025
+29.89%
June 20, 2025
+30.41%

Contineum Therapeutics, Inc. Class A

Contineum Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

Short interest at 11.1% of shares outstanding

28% of the way up its 52-week range

Contineum Therapeutics, Inc. Class A

Contineum Therapeutics, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Below its 50- and 200-day averages

Short interest at 11.1% of shares outstanding

28% of the way up its 52-week range